Stockscreener 앱 받기
1.845
1.65%
0.03
전일 마감가:
$1.815
열려 있는:
$1.7701
하루 거래량:
5,454
Relative Volume:
0.24
시가총액:
$182.47M
수익:
$47.04M
순이익/손실:
$-63.98M
주가수익비율:
-2.2879
EPS:
-0.8064
순현금흐름:
$-34.39M
1주 성능:
+3.07%
1개월 성능:
-15.75%
6개월 성능:
+0.27%
1년 성능:
-11.30%
1일 변동 폭
$1.7701
$1.845
1주일 범위
$1.71
$1.92
52주 변동 폭
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.845 | 182.47M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 개시 | Goldman | Neutral |
Innate Pharma Adr 주식(IPHA)의 최신 뉴스
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India
Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com
H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India
Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
AZN Stock Price and Chart — LSE:AZN - TradingView
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Zacks Investment Research
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat
Innate Pharma Adr (IPHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):